UNION therapeutics completes patient enrollment in the IASOS Phase 2b study of orismilast MR tablet in patients with psoriasis
· Topline results expected in first half of 2023 · Orismilast is a potent next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) Hellerup, Denmark, 11 August 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, announces that it has completed enrollment of the last patient in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of